Delivery Order SPE2DB22D2211-SPE2DB25FSDPF
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $2,710.33 for Humulin R 500 unit/mL KwikPen 3mL insulin pens on July 22, 2025, with a completion date of July 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within the company's broader federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens, valued at $6,578.04. This competitively awarded, firm fixed-price delivery order is set to be completed by August 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a discrete pharmaceutical procurement under AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a $16,119.96 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $26,828.48 to AmerisourceBergen Drug Corp for Humulin R 500 Unit/ML KwikPen 3ML insulin pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 31, 2025, and represents a single transaction under AmerisourceBergen's existing contract vehicle with DLA. The pharmaceutical product will be delivered to the company's distribution center in Conshohocken, Pennsylvania. As a non-set-aside...
- The Defense Logistics Agency awarded a $10,100.87 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Humulin R 500 unit/mL KwikPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's demonstrated capability to compete in...
- The Defense Logistics Agency awarded a delivery order valued at $7,814.46 to AmerisourceBergen Drug Corp for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Humulin R 500 Unit/ML KwikPen 3ML insulin pens, valued at $18,663.84 under a firm fixed-price contract type. This non-set-aside award represents a critical pharmaceutical procurement to support federal healthcare operations, with an ultimate completion date of August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency awarded a $3,252.20 delivery order to AmerisourceBergen Drug Corp for Humulin R 500 Unit/mL KwikPen 3mL insulin pens on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a $2,729.66 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance is scheduled to conclude by July 24, 2025, with fulfillment occurring at the vendor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Humulin R 500 Unit/mL KwikPen 3mL insulin pens, valued at $3,050.78 under firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDPFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,875.52 to AmerisourceBergen Drug Corp for Humulin R 500 Unit/mL KwikPen 3mL insulin pens on August 25, 2025, with completion targeted for August 26, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the delivery from this same location. This delivery order exemplifies AmerisourceBergen's role as a critical vendor within the DLA Medical Supply Chain, supporting military and veteran healthcare systems through the comprehensive pharmaceutical prime vendor contract vehicle. AmerisourceBergen has demonstrated significant capability in federal pharmaceutical procurement through competitive awards spanning a diverse portfolio of medications and medical supplies across multiple therapeutic domains. The IDC serves as a global pharmaceutical support mechanism enabling the company to supply military healthcare programs worldwide, with the DLA planning to establish additional regional Pharmaceutical Prime Vendor Global Program Generation V contracts through multiple award vehicles in the coming years.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.9k | 8/25/25 |